Literature DB >> 11740949

(-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors.

M P Castelli1, I Mocci, A M Sanna, G L Gessa, L Pani.   

Abstract

Amisulpride is a substituted benzamide antipsychotic with nanomolar affinity and high selectivity for dopamine D(2) and dopamine D(3) receptors. The interaction of racemic (+/-)RS amisulpride and its two enantiomers (+)R and (-)S with dopamine D(2) and dopamine D(3) receptors subtypes were compared with that of haloperidol. Binding studies were performed using either [3H]spiperone or [3H]nemonapride in baculovirus/Spodoptera frugiperda insect (Sf-9) cell system expressing either the human dopamine recombinant D(2)long (hD(2L)) or the rat dopamine recombinant D(3) (rD(3)) receptors. K(i) values at dopamine rD(3) receptors were similar regardless of the radioligand used, whereas at hD(2L) receptors values were higher using [3H]spiperone than [3H]nemonapride. However, the rank order of compound potency against radiolabeled spiperone or nemonapride both at dopamine hD(2L) and at dopamine rD(3) receptors was similar. (-)S amisulpride displaced [3H]spiperone or [3H]nemonapride binding from both dopamine hD(2L) or dopamine rD(3) receptors, being twofold more potent than the racemic form and 38-19-fold more potent than (+)R enantiomer. Both racemic and the (-)S enantiomer exhibited 2-4 ([3H]spiperone)- and 3-4 ([3H]nemonapride)-fold higher affinity than haloperidol for dopamine rD(3) receptor, respectively. The (+)R enantiomer has weaker affinity with respect to haloperidol for both dopamine hD(2L) and dopamine rD(3) receptors. Our results show that (-)S amisulpride is the active enantiomer of amisulpride, showing high affinity for dopamine D(3) and dopamine D(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740949     DOI: 10.1016/s0014-2999(01)01484-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice.

Authors:  Timothy J Donahue; Todd M Hillhouse; Kevin A Webster; Richard Young; Eliseu O De Oliveira; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2017-09-18       Impact factor: 4.530

2.  YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.

Authors:  Rui Song; Ri-Fang Yang; Ning Wu; Rui-Bin Su; Jin Li; Xiao-Qing Peng; Xia Li; József Gaál; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Addict Biol       Date:  2011-04-20       Impact factor: 4.280

3.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

Authors:  Béla Kiss; István Laszlovszky; Attila Horváth; Zsolt Némethy; Eva Schmidt; Gyula Bugovics; Károly Fazekas; István Gyertyán; Eva Agai-Csongor; György Domány; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-13       Impact factor: 3.000

4.  Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects.

Authors:  Heiko Graf; Maike Wiegers; Coraline D Metzger; Martin Walter; Georg Grön; Birgit Abler
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

5.  Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7.

Authors:  Vincent Grattan; Andrew R Vaino; Zachary Prensky; Mark S Hixon
Journal:  ACS Omega       Date:  2019-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.